Last night Novavax published the results of their latest vaccine trial (phase 3 trial) – showing this vaccine to be around 90 per cent effective in preventing coronavirus, and being effective against new UK variant.

The results of this vaccine trial look extremely promising. If approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat the virus.

Novavax’s candidate differs from those currently being used in the UK, combining an engineered protein from the virus that causes COVID-19 with a plant-based ingredient to help generate a stronger immune response. Having a diverse portfolio of vaccines increases the chances of ensuring there is a vaccine available for everyone across the UK.

In August, the Government moved quickly to procure 60 million doses from Novavax. The majority of this vaccine will be manufactured on Teesside and delivered during this year, if approved for use. We owe our thanks to the brilliant UK scientists, researchers and volunteers who took part in clinical trials.

This news puts the UK at the forefront of yet another medical breakthrough against Covid. The NHS stands ready to roll this vaccine out as quickly as possible to those most at risk if it is authorised – helping us defeat this virus.

Through the Vaccines Taskforce, the UK has secured early access to 367 million doses of 7 of the most promising vaccines so far. To date, the UK government has invested over £230 million into manufacturing a successful vaccine.